Elicitation of Both Anti HIV-1 Env Humoral and Cellular Immunities by Replicating Vaccinia Prime Sendai Virus Boost Regimen and Boosting by CD40Lm

The Development of CD4 Binding Site Antibodies during HIV-1 Infection

(2012) R. M. Lynch et al.   JOURNAL OF VIROLOGY

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smallpox Vaccine Safety Is Dependent on T Cells and Not B Cells

(2011) Shari N. Gordon et al.   JOURNAL OF INFECTIOUS DISEASES

Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop

(2011) P. L. Moore et al.   JOURNAL OF VIROLOGY

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

The Role of Antibodies in HIV Vaccines

(2010) John R. Mascola et al.   Annual Review of Immunology

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

(2010) M. Juliana McElrath et al.   IMMUNITY

Targeting early infection to prevent HIV-1 mucosal transmission

(2010) Ashley T. Haase   NATURE

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell–mediated immunity

(2010) Luzheng Liu et al.   NATURE MEDICINE

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

(2010) Scott A. Brown et al.   Viruses-Basel

Role of adjuvants in modeling the immune response

(2010) Darrick Carter et al.   Current Opinion in HIV and AIDS

Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8

(2009) Tomoya Saito   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC as adjuvant

(2009) M. Paula Longhi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens

(2009) David M. Asmuth et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Δ that expresses SIV Gag protein

(2009) Hajime Suzuki et al.   VACCINE

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

DNA gag/Adenovirus Type 5 (Ad5) gag and Ad5 gag/Ad5 gag Vaccines Induce Distinct T-Cell Response Profiles

(2008) K. S. Cox et al.   JOURNAL OF VIROLOGY

Gag-Specific Cytotoxic T-Lymphocyte-Based Control of Primary Simian Immunodeficiency Virus Replication in a Vaccine Trial

(2008) M. Kawada et al.   JOURNAL OF VIROLOGY

Toward an AIDS Vaccine

(2008) B. D. Walker et al.   SCIENCE

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

(2008) Jun Liu et al.   VACCINE